Hudson Bay Capital Management
ALGS icon

Hudson Bay Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Hudson Bay Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-241,500
Closed -$1.88M – 1355
2025
Q1 		$1.88M Buy
+241,500
New +$5.29M 0.01% 829

Other funds holding ALGS

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Hudson Bay Capital Management's ALGS Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of Aligos Therapeutics (ALGS) in Q2 2025, closing a stake of 241,500 shares — an estimated $1.88M sold.

Hudson Bay Capital Management first reported a position in ALGS in Q1 2025 and held it in 1 quarter. The position peaked at $1.88M in Q1 2025. 37 funds tracked by Wall St. Rank hold ALGS as of Q2 2025.

  • Hudson Bay Capital Management reported no remaining Aligos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 241,500 Aligos Therapeutics shares in Q2 2025, an estimated $1.88M.
  • Hudson Bay Capital Management first reported a position in Aligos Therapeutics in Q1 2025 and held it in 1 quarter.
  • Hudson Bay Capital Management's Aligos Therapeutics position peaked at $1.88M in Q1 2025.
  • 37 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.